Literature DB >> 12061978

The multiplex-PCR-based detection and genotyping of diarrhoeagenic Escherichia coli in diarrhoeal stools.

G M Matar1, D Abdo, I Khneisser, M Youssef, H Zouheiry, G Abdelnour, H S Harakeh.   

Abstract

In several hospitals in Beirut, Lebanon, 77 isolates of Escherichia coli were successfully derived from the stools of patients with diarrhoeal diseases, by culture on MacConkey or MacConkey-sorbitol agar. When the isolates were screened, using a multiplex PCR, 14 (from 14 different patients) were each found positive for one of the various genes defining the enterotoxigenic (five), enteroinvasive (four), enteroaggregative (three) or enteropathogenic (two) groups. Genotyping of these 14 diarrhoeagenic isolates, by pulsed-field gel electrophoresis, indicated that all were genomically distinct with the exception of two of the enteroaggregative isolates (which were of the same genotype). The E. coli apparently involved in diarrhoeal disease in Beirut therefore belong to at least four different diarrhoeagenic groups and show strain variation within each group. Diarrhoea in the absence of diarrhoeagenic E. coli may be the result of infection with bacteria other than E. coli or viral or parasitic enteropathogens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12061978     DOI: 10.1179/000349802125001032

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  2 in total

1.  Detection of Escherichia coli, Salmonella spp., Shigella spp., Yersinia enterocolitica, Vibrio cholerae, and Campylobacter spp. enteropathogens by 3-reaction multiplex polymerase chain reaction.

Authors:  Oscar G Gómez-Duarte; Jing Bai; Elizabeth Newell
Journal:  Diagn Microbiol Infect Dis       Date:  2008-11-06       Impact factor: 2.803

2.  Antibiogram and beta-lactamase genes among cefotaxime resistant E. coli from wastewater treatment plant.

Authors:  Anthony Ayodeji Adegoke; Chibuzor Ezinne Madu; Olayinka Ayobami Aiyegoro; Thor Axel Stenström; Anthony Ifeanyi Okoh
Journal:  Antimicrob Resist Infect Control       Date:  2020-03-12       Impact factor: 4.887

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.